Astex uses a fragment-based approach to discover and develop small molecule molecularly targeted drugs for the treatment of cancer and other human diseases with significant unmet medical need.
Astex Therapeutics was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both of University of Cambridge) and Dr Roberto Solari, currently Chief Executive of Medical Research Council Technology. Astex Therapeutics (formerly Astex Technology) is a biotechnology company that discovers and develops molecularly-targeted drugs in areas of unmet medical need. The company's primary focus is in oncology. Astex has a broad and expanding pipeline of products in clinical and pre-clinical development generated using its proprietary drug discovery engine, Pyramid.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Contact details
To view this information, you must subscribe to PL Intelligence.
Head office
Astex Therapeutics Limited
436 Cambridge Science Park
Milton Road
Cambridge
Cambridgeshire
CB4 0QA United Kingdom
All rights reserved. Terms and Conditions | Contact us
